Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS have?
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS has 14 citations in the OpenAlex counts ScholarIQ stores.
When was Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS published?
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS has 2023 year in the ScholarIQ index.
What is the open-access status of Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS?
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS has gold oa status in the ScholarIQ index.
What is the DOI of Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS?
The DOI for Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS is on the source record.
What is the PMID of Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS?
The PMID for Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS is on the source record.
What is the OpenAlex record for Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS?
The OpenAlex for Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS is on the source record.